Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non Operating Income (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Non Operating Income data on record, last reported at -$1.2 million in Q3 2025.

  • For Q3 2025, Non Operating Income fell 2527.27% year-over-year to -$1.2 million; the TTM value through Sep 2025 reached -$3.3 million, down 164.64%, while the annual FY2024 figure was -$2.1 million, 220.73% down from the prior year.
  • Non Operating Income reached -$1.2 million in Q3 2025 per TNXP's latest filing, up from -$2.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $897000.0 in Q1 2023 and bottomed at -$2.0 million in Q2 2025.
  • Average Non Operating Income over 3 years is -$253818.2, with a median of -$44000.0 recorded in 2024.
  • Peak YoY movement for Non Operating Income: tumbled 8014.29% in 2024, then surged 166.44% in 2025.
  • A 3-year view of Non Operating Income shows it stood at $7000.0 in 2023, then crashed by 8014.29% to -$554000.0 in 2024, then crashed by 108.66% to -$1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$1.2 million in Q3 2025, -$2.0 million in Q2 2025, and $394000.0 in Q1 2025.